Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Operating Expenses (2016 - 2026)

Amphastar Pharmaceuticals has reported Other Operating Expenses over the past 13 years, most recently at $19.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 82.32% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $52.6 million, up 35.0%, while the annual FY2025 figure was $43.9 million, 16.09% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $19.0 million at Amphastar Pharmaceuticals, up from $11.5 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $19.0 million in Q4 2025 and troughed at $4.1 million in Q4 2021.
  • A 5-year average of $8.0 million and a median of $6.9 million in 2023 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 82.32% in 2025 and fell as far as 0.54% in 2025.
  • Year by year, Other Operating Expenses stood at $4.1 million in 2021, then skyrocketed by 34.28% to $5.5 million in 2022, then skyrocketed by 57.51% to $8.6 million in 2023, then rose by 20.94% to $10.4 million in 2024, then surged by 82.32% to $19.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for AMPH at $19.0 million in Q4 2025, $11.5 million in Q3 2025, and $10.2 million in Q2 2025.